Nice

News

NICE recommends regular NHS funding for Roche's lymphoma dru...

NICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning a previous rejection.

Views & Analysis

How does HTA for orphan drugs differ across Europe?

New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe.

News

NICE backs kidney cancer combination from Merck KGaA and Pfi...

NICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first line option for kidney cancer patients for NHS patients in England.

News

NICE backs NHS use of Takeda’s Adcetris for rare blood cance...

Takeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form of non-Hodgkin lymphoma (NHL), says NICE.

News

NICE says no to Novartis’ Mayzent in secondary progressive M...

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this

Views & Analysis